Your browser doesn't support javascript.
loading
Advances in the clinical management of high-risk Wilms tumors.
Ortiz, Michael V; Koenig, Christa; Armstrong, Amy E; Brok, Jesper; de Camargo, Beatriz; Mavinkurve-Groothuis, Annelies M C; Herrera, Thelma B Velasquez; Venkatramani, Rajkumar; Woods, Andrew D; Dome, Jeffrey S; Spreafico, Filippo.
Afiliación
  • Ortiz MV; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Koenig C; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Armstrong AE; Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Brok J; Developmental Biology and Cancer Research and Teaching Department, University College London Great Ormond Street Institute of Child Health, London, UK.
  • de Camargo B; Department of Pediatric Oncology and Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Mavinkurve-Groothuis AMC; Pediatric Hematology and Oncology Program, Research Center, Instituto Nacional de Cancer, Rio de Janeiro, Brazil.
  • Herrera TBV; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • Venkatramani R; Unidad Nacional de Oncologia Pediatrica, Guatemala City, Guatemala.
  • Woods AD; Department of Pediatrics, Division of Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
  • Dome JS; Children's Cancer Therapy Development Institute, Beaverton, Oregon, USA.
  • Spreafico F; Division of Oncology, Children's National Hospital and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Pediatr Blood Cancer ; 70 Suppl 2: e30342, 2023 05.
Article en En | MEDLINE | ID: mdl-37096797
Outcomes are excellent for the majority of patients with Wilms tumors (WT). However, there remain WT subgroups for which the survival rate is approximately 50% or lower. Acknowledging that the composition of this high-risk group has changed over time reflecting improvements in therapy, we introduce the authors' view of the historical and current approach to the classification and treatment of high-risk WT. For this review, we consider high-risk WT to include patients with newly diagnosed metastatic blastemal-type or diffuse anaplastic histology, those who relapse after having been initially treated with three or more different chemotherapeutics, or those who relapse more than once. In certain low- or low middle-income settings, socio-economic factors expand the definition of what constitutes a high-risk WT. As conventional therapies are inadequate to cure the majority of high-risk WT patients, advancement of laboratory and early-phase clinical investigations to identify active agents is urgently needed.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumor de Wilms / Neoplasias Renales Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumor de Wilms / Neoplasias Renales Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos